Health

Results: 5737-5748 of 8738

WuXi Biologics and Medigene Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell Engagers

The Nichi BRITE Beta 1,3-1,6 Glucan is produced as an exo-polysaccharide by Aureobasidium Pullulans in a GMP certified facility in Japan and is water soluble. The subjects of Nichi BRITE group in the study were given 250mg Beta glucan as an active ingredient per day for 22 days as an adjuvant, while control group had a placebo instead; both groups were given standard of care treatment. The quantity consumed during the study by each patient is equivalent to four boxes of Nichi BRITE, which comes in a box of 24 sachets, 1.5-gram granule as content with 63 mg active beta glucan as ingredient per sachet. Oral administration was undertaken when possible, and when it was not possible, administration was through feeding gastrostomy or nasogastric tube. No adverse reactions were observed. The efficacy in terms of immune enhancement, cancer biomarker reduction and longer mean survival were reported with Nichi Brite as an adjuvant. (Graphic: Business Wire)

Nichi BRITE Beta glucan as an onco-nutrition supplement in pancreatic cancer; Encouraging clinical results reported by Chikamori Hospital, Japan.

Medscape Global Launches the Affinity™ Platform: Offering Behavioural Insights from Over 13 Million Healthcare Professionals

PR Newswire associated0

WestGene to Advance Clinical Trials Following Dual IND Approvals for World's First EB Virus-Related mRNA Therapeutic Cancer Vaccine

Vertex Announces CASGEVY™ Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia in England

Parse Biosciences Partners with Taiwan-based Prisma Biotech to Extend Reach in Asia

PR Newswire associated0

Endo to Host Investor Call on Second Quarter 2024 Financial Results

PR Newswire associated0

PeproMene Bio announced study demonstrating strong polyfunctionality of novel chimeric antigen receptor (CAR) T cells

PR Newswire associated0

Abbott Enters Global Partnership to Connect Its World-Leading Continuous Glucose Monitoring System with Medtronic's Insulin Delivery Devices

Alnylam to Present Detailed Results from the HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress 2024

PR Newswire associated0

AI that Detects Hidden Heart Disease is a Finalist for British Heart Foundation's 'Research Project of the Year' Award

Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)